Pharmacokinetics of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ, NSC 224070) during a phase I clinical trial
- 1 February 1990
- journal article
- research article
- Published by Elsevier in European Journal of Cancer and Clinical Oncology
- Vol. 26 (2) , 107-112
- https://doi.org/10.1016/0277-5379(90)90291-z
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Determination of diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone in plasma by solid-phase extraction and high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1988
- Mechanism for the Reductive Activation of DiaziquoneJournal of Pharmaceutical Sciences, 1985
- Stability of 2,5-diaziridinyl-3,6-bis(2-hydroxyethylamino)-1,4-benzoquinone (BZQ; NSC 224070) in aqueous solutions by high-performance liquid chromatographyInvestigational New Drugs, 1985
- Diaziquone (AZQ)Investigational New Drugs, 1983
- PHASE-II AND PHARMACOKINETIC STUDY OF AZIRIDINYLBENZOQUINONE [2,5-DIAZIRIDINYL-3,6-BIS(CARBOETHOXYAMINO)-1,4-BENZOQUINONE, DIAZIQUONE, NSC-182986] IN HIGH-GRADE GLIOMAS1983
- 2,5-Diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone I: Kinetics in Aqueous Solutions by High-Performance Liquid ChromatographyJournal of Pharmaceutical Sciences, 1981
- Potential CNS Antitumor Agents VI: Aziridinylbenzoquinones IIIJournal of Pharmaceutical Sciences, 1979
- Potential central nervous system antitumor agents. Aziridinylbenzoquinones. 2Journal of Medicinal Chemistry, 1976
- Clinical PharmacokineticsNew England Journal of Medicine, 1975